Skip to main content

Advertisement

Table 5 HPV incidence in males participating in circumcision clinical trials

From: Epidemiology of HPV genotypes in Uganda and the role of the current preventive vaccines: A systematic review

Author Area, subjects Study design HPV test HPV incident casesc and ratesd for type-specific genotypes per 100 PYs Proportions of type-specific incident infections at 24-month follow-up Risk Ratio (RR) and 95% CI for HR* and multiple infections
Serwadda et al., 2010 [59] Rakai district, uncircumcised HIV positive men aged 15-49 years; 103 men in intervention group and 107 men in control group Randomized controlled trial Roche HPV linear array At 24 months
HR-HPV incident casesc
Intervention group, 42 cases
Control group, 57 cases
Multiple infectionincident cases c
Intervention group, 9.9 cases
Control group, 24.7 cases
Incident proportions At 24 months
RR for HR-HPV types = 0.74 (0.54-1.01)
RR for multiple infection = 0.04 (0.19-0.84).
         Interventiond
(%)
Controld
(%)
 
        HPV 16
HPV 18
HPV 45
HPV 51
HPV 52
5.8
4.3
4.1
5.4
10.1
14.9
11.1
10.3
13.9
8.2
 
Gray, et al. 2010 [60] Rakai district, uncircumcised HIV negative men aged 15-49 years; 441 men in intervention and 399 men in control group Randomized controlled trial Roche HPV linear array At 24 months
HR-HPV incident cases c
Intervention group, 19.7 cases
Control group, 29.4 cases
Multiple infection incident cases c
Intervention group, 6.7 cases
Control group, 14.8 cases
Type specific incidence rates d
    At 24 months
RR for HR-HPV types = 0.67 (0.51-0.89)
RR for multiple infections = 0.45 (0.28-0.73)
      Intervention Control     
      Incidence/100 PYs     
     HPV 16
HPV 18
HPV 45
HPV 51
HPV 52
3.6
1.6
1.6
4.0
1.6
4.8
5.3
2.4
5.3
3.6
    
  1. HR* = High Risk
  2. CI = Confidence Intervals
  3. PYs = Person Years
  4. c Denominator include all women tested
  5. d Denominator include women with HR-HPV